Preferred Label : Matrix-M;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3501621/fr/nuvaxovid-proteine-spike-de-sars-cov-2-et-un-adjuvant-matrix-m-covid-19
2024
false
false
false
France
vaccine potency
vaccination
COVID-19
COVID-19 Vaccines
insurance, health, reimbursement
adolescent
adult
injections, intramuscular
Adjuvants, Vaccine
Matrix-M
evaluation of the transparency committee
SARS-CoV-2
spike protein, SARS-CoV-2

---
Nous contacter.
25/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.